Nothing Special   »   [go: up one dir, main page]

EA200701786A1 - Поливалентная противогриппозная иммуногенная композиция - Google Patents

Поливалентная противогриппозная иммуногенная композиция

Info

Publication number
EA200701786A1
EA200701786A1 EA200701786A EA200701786A EA200701786A1 EA 200701786 A1 EA200701786 A1 EA 200701786A1 EA 200701786 A EA200701786 A EA 200701786A EA 200701786 A EA200701786 A EA 200701786A EA 200701786 A1 EA200701786 A1 EA 200701786A1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
antigripose
immunogenous
polyvalent
composition
Prior art date
Application number
EA200701786A
Other languages
English (en)
Other versions
EA011419B1 (ru
Inventor
Эмманнуэль Жюль Ханон
Жанк Стефенн
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0505989A external-priority patent/GB0505989D0/en
Priority claimed from GB0506004A external-priority patent/GB0506004D0/en
Priority claimed from GB0506001A external-priority patent/GB0506001D0/en
Priority claimed from GB0506000A external-priority patent/GB0506000D0/en
Priority claimed from GB0505998A external-priority patent/GB0505998D0/en
Priority claimed from GB0510596A external-priority patent/GB0510596D0/en
Priority claimed from GB0510591A external-priority patent/GB0510591D0/en
Priority claimed from GB0510593A external-priority patent/GB0510593D0/en
Priority claimed from GB0510589A external-priority patent/GB0510589D0/en
Priority claimed from GB0510598A external-priority patent/GB0510598D0/en
Priority claimed from GB0603789A external-priority patent/GB0603789D0/en
Priority claimed from GB0603788A external-priority patent/GB0603788D0/en
Priority claimed from GB0603790A external-priority patent/GB0603790D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200701786A1 publication Critical patent/EA200701786A1/ru
Publication of EA011419B1 publication Critical patent/EA011419B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к противогриппозным вакцинным композициям и режимам вакцинации с целью иммунизации против заболевания гриппом, их применению в медицине, в частности, их применению в усилении иммунных ответов на различные антигены, и к способам их изготовления. В частности, данное изобретение относится к поливалентным противогриппозным иммуногенным композициям, содержащим антиген вируса гриппа или его антигенный препарат по меньшей мере из двух штаммов вируса гриппа, где по меньшей мере один штамм связан со вспышкой пандемии или может быть связан со вспышкой пандемии, в комбинации с адъювантом в виде эмульсии типа масло-в-воде.
EA200701786A 2005-03-23 2006-03-21 Поливалентная противогриппозная иммуногенная композиция EA011419B1 (ru)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition
PCT/EP2006/002837 WO2006100110A1 (en) 2005-03-23 2006-03-21 Novel composition

Publications (2)

Publication Number Publication Date
EA200701786A1 true EA200701786A1 (ru) 2008-04-28
EA011419B1 EA011419B1 (ru) 2009-02-27

Family

ID=36441219

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200701787A EA200701787A1 (ru) 2005-03-23 2006-03-21 Иммунная композиция, способ ее изготовления, ее применение и способ вакцинации
EA200701786A EA011419B1 (ru) 2005-03-23 2006-03-21 Поливалентная противогриппозная иммуногенная композиция
EA200701785A EA011393B1 (ru) 2005-03-23 2006-03-21 Применение вируса гриппа и адъюванта на основе эмульсии "масло в воде" для индуцирования cd4 т-клеточного ответа и/или улучшенного ответа, основанного на в-клетках памяти

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200701787A EA200701787A1 (ru) 2005-03-23 2006-03-21 Иммунная композиция, способ ее изготовления, ее применение и способ вакцинации

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200701785A EA011393B1 (ru) 2005-03-23 2006-03-21 Применение вируса гриппа и адъюванта на основе эмульсии "масло в воде" для индуцирования cd4 т-клеточного ответа и/или улучшенного ответа, основанного на в-клетках памяти

Country Status (24)

Country Link
US (5) US20090081253A1 (ru)
EP (4) EP1861120B1 (ru)
JP (4) JP5770414B2 (ru)
KR (5) KR20070116650A (ru)
AR (3) AR054020A1 (ru)
AU (3) AU2006226459A1 (ru)
CA (3) CA2603180C (ru)
CY (1) CY1117874T1 (ru)
DK (1) DK1861120T3 (ru)
EA (3) EA200701787A1 (ru)
ES (1) ES2585810T3 (ru)
HR (1) HRP20160816T1 (ru)
HU (1) HUE027837T2 (ru)
IL (3) IL185897A (ru)
MA (3) MA30298B1 (ru)
MX (3) MX2007011775A (ru)
NO (3) NO20074635L (ru)
NZ (2) NZ561823A (ru)
PE (3) PE20061300A1 (ru)
PL (1) PL1861120T3 (ru)
PT (1) PT1861120T (ru)
SI (1) SI1861120T1 (ru)
TW (3) TW200722101A (ru)
WO (3) WO2006100111A1 (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
TW200722101A (en) * 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628397C (en) * 2005-11-04 2013-08-20 Novartis Vaccines And Diagnostics S.R.L. Changing th1/th2 balance in split influenza vaccines with adjuvants
PL1945252T3 (pl) * 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
JP2009514844A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
TW200745158A (en) 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009534303A (ja) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
WO2007144772A2 (en) 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
SI2043682T1 (sl) * 2006-07-17 2014-07-31 Glaxosmithkline Biologicals S.A. Influenčno cepivo
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
PL2086582T3 (pl) * 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
EP2679240A1 (en) * 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
NZ594892A (en) * 2007-02-23 2012-12-21 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
NZ583377A (en) * 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
GB0810305D0 (en) † 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
TWI376385B (en) * 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
WO2009115917A2 (en) * 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2009128950A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
CA2729248A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
SI2396030T1 (sl) 2009-02-10 2015-12-31 Novartis Ag Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
EP2289575B1 (de) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Medizinisches Implantat enthaltend eine antioxidative Substanz
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
SI2506834T1 (sl) 2009-12-03 2016-04-29 Novartis Ag Cirkulacija sestavin med homogenizacijo in mikrofluidizacijo emulzij
AU2010325751B2 (en) * 2009-12-03 2014-05-08 Seqirus UK Limited Arranging interaction and back pressure chambers for microfluidization
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
JP5754860B2 (ja) 2009-12-03 2015-07-29 ノバルティス アーゲー ワクチンアジュバントの製造の間の親水性濾過
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Seqirus UK Limited Hydrophilic filtration during manufacture of vaccine adjuvants
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN102802664B (zh) * 2009-12-22 2017-04-05 赛诺菲巴斯德有限公司 免疫原性组合物
CN102740872A (zh) * 2010-01-06 2012-10-17 威星内特公司 用于在老年人中提供保护性免疫的方法和组合物
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
RU2527688C2 (ru) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
HUE044434T2 (hu) * 2012-12-28 2019-10-28 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Nazális influenzavakcina-készítmény
KR20160030097A (ko) * 2013-05-10 2016-03-16 노파르티스 아게 인플루엔자 백신에서 기면증 위험의 방지
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
JP2017528511A (ja) * 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
US20200306364A1 (en) * 2017-11-30 2020-10-01 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP3917567A1 (en) * 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Oil/surfactant mixtures for self-emulsification
MX2022007691A (es) * 2019-12-20 2022-07-19 Fresenius Kabi Austria Gmbh Metodo para producir emulsiones aceite en agua.
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов
EP4171629A1 (en) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
WO2022046634A1 (en) 2020-08-24 2022-03-03 Sanofi Pasteur Inc. Vaccines against sars-cov-2 infections
JP2023538665A (ja) 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
KR102270165B1 (ko) 2020-10-22 2021-06-28 한국화학연구원 세정제 조성물
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610A1 (fr) * 1975-12-03 1977-07-01 Zhdanovsky Z Tyazhelogo Mash Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
EP0382271B1 (en) * 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (en) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Digital servo drive
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1994019013A1 (en) 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9506885A (pt) 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
BR9908599A (pt) * 1998-03-09 2000-11-14 Smithkline Beecham Biolog Composições combinadas de vacina
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
EP1091928B1 (fr) 1998-06-30 2007-02-28 OM Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
PL211762B1 (pl) 2000-01-31 2012-06-29 Smithkline Beecham Biolog Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
CA2559371C (en) * 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
SI2043682T1 (sl) * 2006-07-17 2014-07-31 Glaxosmithkline Biologicals S.A. Influenčno cepivo
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition

Also Published As

Publication number Publication date
HUE027837T2 (en) 2016-11-28
CA2603180C (en) 2015-10-13
EA200701785A1 (ru) 2008-04-28
WO2006100110A1 (en) 2006-09-28
MA29715B1 (fr) 2008-09-01
ES2585810T3 (es) 2016-10-10
AR052625A1 (es) 2007-03-21
KR101916787B1 (ko) 2019-01-24
EP2397153A1 (en) 2011-12-21
HRP20160816T1 (hr) 2016-08-12
NZ561822A (en) 2010-04-30
CA2601022A1 (en) 2006-09-28
AU2006226458A1 (en) 2006-09-28
US9730999B2 (en) 2017-08-15
JP5869744B2 (ja) 2016-02-24
NO20074635L (no) 2007-12-19
PE20061428A1 (es) 2007-01-16
IL185901A0 (en) 2008-01-06
KR20070116650A (ko) 2007-12-10
EP1861120B1 (en) 2016-05-25
MX2007011756A (es) 2008-03-11
US20110287054A1 (en) 2011-11-24
IL185897A0 (en) 2008-01-06
WO2006100111A1 (en) 2006-09-28
PT1861120T (pt) 2016-08-18
CA2601022C (en) 2023-03-07
CA2602456A1 (en) 2006-09-28
DK1861120T3 (en) 2016-07-25
SI1861120T1 (sl) 2016-09-30
CY1117874T1 (el) 2017-05-17
JP5770414B2 (ja) 2015-08-26
JP2014129359A (ja) 2014-07-10
KR20160064249A (ko) 2016-06-07
PE20061300A1 (es) 2006-12-23
PE20061387A1 (es) 2007-01-19
IL185906A0 (en) 2008-01-06
IL185897A (en) 2015-11-30
MA30298B1 (fr) 2009-04-01
JP2008534466A (ja) 2008-08-28
EA011419B1 (ru) 2009-02-27
NO20074638L (no) 2007-12-19
US20080171063A1 (en) 2008-07-17
AR054020A1 (es) 2007-05-30
US20140363474A1 (en) 2014-12-11
EA011393B1 (ru) 2009-02-27
TW200722101A (en) 2007-06-16
AU2006226543A1 (en) 2006-09-28
TW200700079A (en) 2007-01-01
WO2006100109A1 (en) 2006-09-28
US20090081253A1 (en) 2009-03-26
EP1861120A1 (en) 2007-12-05
MX2007011748A (es) 2008-03-11
CA2603180A1 (en) 2006-09-28
JP2008534465A (ja) 2008-08-28
KR20070116651A (ko) 2007-12-10
JP2008534467A (ja) 2008-08-28
PL1861120T3 (pl) 2016-11-30
KR20140004815A (ko) 2014-01-13
NZ561823A (en) 2010-04-30
NO20074930L (no) 2007-12-07
AU2006226543B2 (en) 2011-10-06
EA200701787A1 (ru) 2008-08-29
MX2007011775A (es) 2008-03-11
AR053833A1 (es) 2007-05-23
TW200700078A (en) 2007-01-01
AU2006226459A1 (en) 2006-09-28
AU2006226458B2 (en) 2012-08-30
KR20070116652A (ko) 2007-12-10
EP1861122A1 (en) 2007-12-05
EP1863529A1 (en) 2007-12-12
MA29342B1 (fr) 2008-03-03
US20080181911A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
Honda-Okubo et al. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses
EA200900024A1 (ru) Противогриппозная вакцина
BRPI0621886A8 (pt) composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
Ghendon et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CY1112572T1 (el) Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
AR080111A1 (es) Metodos y composiciones de inmunizacion
Romeli et al. Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials
Dong et al. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
EA201690115A1 (ru) Комбинированные иммуногенные композиции
Morçӧl et al. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice
Cargnelutti et al. Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
Jiang et al. Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines
Onishi et al. Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets
EA201070014A1 (ru) Внутрикожная вакцина против гриппа
WO2021216560A3 (en) Vaccine compositions for sars-related coronaviruses and methods of use
SG160386A1 (en) Novel composition
Kang et al. HA1-2-fljB vaccine induces immune responses against pandemic swine-origin H1N1 influenza virus in mice

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM